# Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics

> **NCT01610154** · PHASE4 · COMPLETED · sponsor: **Guangwei Li** · enrollment: 85 (actual)

## Conditions studied

- Insulin Secretion
- Insulin Resistance

## Interventions

- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT01610154
- **Lead sponsor:** Guangwei Li
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-08
- **Final completion:** 2015-06
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2017-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01610154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01610154, "Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01610154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*